The present study investigated Boerhaavia diffusa extract against Mycobacterium tuberculosis H37Rv (M.tb) infection in vitro and explored the underlying mechanism. The study demonstrated that Boerhaavia diffusa extract significantly (p < 0.05) reduced RAW 264.7 and A549 cell viability in concentration dependent manner. In BEAS-2B, NuLi-1 cells and splenocytes no significant (p > 0.05) reduction in viability was observed on treatment with 2.5 to 20 mg/L concentrations of Boerhaavia diffusa. The M. tb‑induced increase in TNF‑α expression was significantly (p < 0.05) reversed by Boerhaavia diffusa treatment in RAW 264.7 and BEAS-2B cells. Moreover, Boerhaavia diffusa treatment significantly (p < 0.05) inhibited M.tb‑induced increase in IL-6 and IL‑1β expression in RAW 264.7 and BEAS-2B cells. Boerhaavia diffusa treatment of RAW 264.7 and BEAS-2B cells significantly (p < 0.05) reversed M.tb‑induced increase in iNOS and COX‑2 expression. Additionally, in Boerhaavia diffusa treated cells M.tb‑induced increase in NO release was significantly (p < 0.05) reduced compared to untreated cells. In summary, Boerhaavia diffusa treatment inhibits pro-inflammatory cytokine production, NO release and regulate immunomodulatory mediators in M.tb‑infected RAW 264.7 and BEAS-2B cells. Therefore, Boerhaavia diffusa may be developed as a therapeutic agent for treatment of M.tb‑infection.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Ahmad, Z., Makaya, H.N., and Grosset, J.H., History of TB drug discovery: early evaluation studies and lessons learnt from them. Antituberculosis chemotherapy, Prog. Respir. Res., 2011, vol. 40, pp. 1–8.
WHO Global tuberculosis report, 2016. http://reliefweb.int/sites/reliefweb.int/files/resources/gtbr2016_main_text.pdf.
Lalloo, U.G., Pillay, S., Mngqibisa, R., et al., HIV and COPD: a conspiracy of risks, Respirology, 2016, vol. 21, pp. 1166–1172.
Lechartier, B., Rybniker, J., Zumla, A., et al., Tuberculosis drug discovery in the post genomic era, EMBO Mol. Med., 2014, vol. 6, pp. 158–168.
Coussens, L.M. and Werb, Z., Inflammation and cancer, Nature, 2002, vol. 420, pp. 860–867.
Lee Y.J., Han, S.B., Nam, S.Y., Oh, K.W., and Hong, J.T., Inflammation and Alzheimer’s disease, Arch. Pharm. Res., 2010, vol. 33, pp. 1539–1556.
Achoui, M., Appleton, D., Abdulla, M.A., Awang, K., Mohd, M.A., and Mustafa, M.R., In vitro and in vivo anti-inflammatory activity of 17-O acetylacuminolide through the inhibition of cytokines, NF-kB translocation and IKKβ activity, PLoS One, 2010, vol. 5, e15105.
Zumla, A., Rao, M., Parida, S.K., Keshavjee, S., Cassell, G., Wallis, R., Axelsson-Robertsson, R., Do-herty, M., and Maeurer, M., Inflammation and tuberculosis: host-directed therapies, J. Intern. Med., 2014, vol. 277, pp. 373–387.
Roy, S., Sharma, S., Sharma, M., Aggarwal, R., and Bose, M., Induction of nitric oxide release from the human alveolar epithelial cell line A549: an in vitro correlate of innate immune response to mycobacterium tuberculosis, Immunology, 2004, vol. 112, pp. 471–480.
Rajpoot, K. and Mishra, R.N., Boerhaavia diffusa roots (Punarnava mool)—review as rasayan (rejuvenator/antiaging), Int. J. Res. Pharm. Biomed. Sci., 2011, vol. 2, pp. 1451–1460.
Nalamolu, R.K., Boini, K.M., and Nammi, S., Effect of chronic administration of Boerhaavia diffusa Linn. leaf extract on experimental diabetes in rats, Trop. J. Pharm. Res., 2004, vol. 3, pp. 305–309.
Bhalla, T.N., Gupta, M.B., Sheth, P.K., and Bharga-va, K.P., Anti-inflammatory activity of Boerhaavia diffusa, Indian J. Physiol. Pharmacol., 1968, vol. 12, p. 37.
Medzhitov, R., Origin and physiological roles of inflammation, Nature, 2008, vol. 454, pp. 428–435.
Subbian, S., Tsenova, L., O’Brien, P., Yang, G., Koo, M.S., Peixoto, B., Fallows, D., Dartois, V., Muller, G., and Kaplan, G., Phosphodiesterase 4 inhibition alters gene expression and improves isoniazid mediated clearance of mycobacterium tuberculosis in rabbit lungs, PLoS Pathog., 2011, vol. 7, p. e. 1002262.
Bermudez, L.E. and Goodman, J., Mycobacterium tuberculosis invades and replicates within type ii alveolar cells, Infect. Immunol., 1996, vol. 64, pp. 1400–1406.
Moita, E., Gil-Izquierdo, A., Sousa, C., Ferreres, F., Silva, L.R., Valentão, P., Domínguez-Perles, R., Baenas, N., and Andrade, P.B., Integrated analysis of COX-2 and iNOS derived inflammatory mediators in LPS-stimulated RAW macrophages pre-exposed to Echium plantagineum L. bee pollen extract, PLoS One, 2013, vol. 8, p. e. 59131.
Weinberg, J.B., Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation, Immunol. Res., 2000, vol. 22, pp. 319–341.
Roy, S., Sharma, S., Sharma, M., Aggarwal, R., and Bose, M., Induction of nitric oxide release from the human alveolar epithelial cell line A549: an in vitro correlate of innate immune response to Mycobacterium tuberculosis, Immunology, 2004, vol. 112, pp. 471–480.
The authors declare that they have no conflict of interest.
COMPLIANCE WITH ETHICAL STANDARDS
The study was approved by Animal Ethics Committee, Second Affiliated Hospital of Xi’an Jiaotong University. All the experiments were performed in accordance with the guidelines issued by the United States National Institutes of Health.
About this article
Cite this article
Zheng, Q., Ren, H. & Yang, S. Boerhaavia diffusa Extract Acts as a Specific Antituberculosis Agent in Vitro Against Mycobacterium tuberculosis H37Rv Infection. Dokl Biochem Biophys 499, 266–272 (2021). https://doi.org/10.1134/S160767292104013X
- Boerhaavia diffusa extract